Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 56-Day , Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake in Overweight and Obese Patients (TULIP).

Trial Profile

A 56-Day , Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Effect of Lorcaserin Hydrochloride on Energy Metabolism and Food Intake in Overweight and Obese Patients (TULIP).

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lorcaserin (Primary)
  • Indications Obesity
  • Focus Pharmacodynamics
  • Acronyms TULIP
  • Sponsors Arena Pharmaceuticals; Eisai Inc
  • Most Recent Events

    • 02 Nov 2015 Results of post-hoc analysis of data from this trial will be presented at the ObesityWeek 2015 hosted by The Obesity Society and the American Society for Metabolic and Bariatric Surgery, according to an Eisai Co Ltd media release.
    • 18 Jan 2011 Planned number of patients changed from 56 to 57.
    • 11 Nov 2010 Energy intake and appetite outcomes were reported at the 2010 Annual Meeting of the North American Association for the Study of Obesity.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top